New strategies in chronic lymphocytic leukemia: Shifting treatment paradigms

Farrukh T. Awan, John C. Byrd

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the surrounding microenvironment influences leukemia cell survival. The complexity of CLL with respect to different chromosomal aberrations, lack of a common aberrant signaling pathway activation, and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid leukemia. The upcoming therapeutic era we are entering with the B-cell receptor (BCR) tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle. Indeed, for the large majority of patients, it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy. Where other very active targeted agents such as ABT-199, therapeutic antibodies, and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer.

Original languageEnglish (US)
Pages (from-to)5869-5874
Number of pages6
JournalClinical Cancer Research
Volume20
Issue number23
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Immune System Diseases
Receptor Protein-Tyrosine Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-Cell Antigen Receptor
Chromosome Aberrations
Cell Survival
Leukemia
Phosphotransferases
Therapeutics
Clinical Trials
Drug Therapy
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New strategies in chronic lymphocytic leukemia : Shifting treatment paradigms. / Awan, Farrukh T.; Byrd, John C.

In: Clinical Cancer Research, Vol. 20, No. 23, 01.12.2014, p. 5869-5874.

Research output: Contribution to journalArticle

@article{329c12f4be8e4559ac01eacd36556f45,
title = "New strategies in chronic lymphocytic leukemia: Shifting treatment paradigms",
abstract = "Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the surrounding microenvironment influences leukemia cell survival. The complexity of CLL with respect to different chromosomal aberrations, lack of a common aberrant signaling pathway activation, and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid leukemia. The upcoming therapeutic era we are entering with the B-cell receptor (BCR) tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle. Indeed, for the large majority of patients, it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy. Where other very active targeted agents such as ABT-199, therapeutic antibodies, and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer.",
author = "Awan, {Farrukh T.} and Byrd, {John C.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-14-1889",
language = "English (US)",
volume = "20",
pages = "5869--5874",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - New strategies in chronic lymphocytic leukemia

T2 - Shifting treatment paradigms

AU - Awan, Farrukh T.

AU - Byrd, John C.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the surrounding microenvironment influences leukemia cell survival. The complexity of CLL with respect to different chromosomal aberrations, lack of a common aberrant signaling pathway activation, and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid leukemia. The upcoming therapeutic era we are entering with the B-cell receptor (BCR) tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle. Indeed, for the large majority of patients, it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy. Where other very active targeted agents such as ABT-199, therapeutic antibodies, and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer.

AB - Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the surrounding microenvironment influences leukemia cell survival. The complexity of CLL with respect to different chromosomal aberrations, lack of a common aberrant signaling pathway activation, and associated immune suppression of the disease has been seen a major stumbling block for developing a single targeted therapy similar to imatinib used in chronic myeloid leukemia. The upcoming therapeutic era we are entering with the B-cell receptor (BCR) tyrosine kinase inhibitors ibrutinib and idelalisib appears to be overcoming this obstacle. Indeed, for the large majority of patients, it appears that application of BCR kinase inhibitors can promote durable remissions without the need for chemotherapy. Where other very active targeted agents such as ABT-199, therapeutic antibodies, and chimeric antigen receptor-modified T-cells will be used in CLL also represents a major question that future clinical trials will answer.

UR - http://www.scopus.com/inward/record.url?scp=84918536030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918536030&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-1889

DO - 10.1158/1078-0432.CCR-14-1889

M3 - Article

C2 - 25294898

AN - SCOPUS:84918536030

VL - 20

SP - 5869

EP - 5874

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -